With regard to lung cancer, a review, which included 23 studies, concluded that elevated blood CEA levels in patients with NSCLC are associated with an increased risk of relapse and mortality, irrespective of the treatment modality employed [30]. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.